{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:28Z","timestamp":1783734388115,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Revance Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation approved for the treatment of glabellar lines. The efficacy, safety, and extended duration of response of DAXI 40 U for glabellar lines were demonstrated in 2 Phase 3, randomized, double-blind studies (SAKURA 1 and 2) and a Phase 3 open-label trial (SAKURA 3).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the efficacy and safety of the first DAXI 40 U treatment received in SAKURA 1, 2, or 3 across age and race subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with moderate-to-severe glabellar lines (Investigator Global Assessment\u2013Frown Wrinkle Severity [IGA-FWS] and Patient FWS [PFWS] scales) were evaluated for glabellar line severity for \u226436 weeks after the first DAXI treatment. Efficacy and safety were analyzed by age (18-45, &amp;gt;45-55, and &amp;gt;55 years) and race (Asian, Black and African American, and White).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 2785 patients were included in the efficacy analysis. The proportion of patients achieving none or mild glabellar line severity at maximum frown (IGA-FWS) after DAXI treatment was high in all age and race subgroups (&amp;gt;96% at Week 4). Glabellar line severity of none or mild by composite IGA-FWS and PFWS rating was maintained for a median of 24.0 weeks in all age subgroups, and for 27.0, 25.3, and 24.0 weeks in the Asian, Black and African American, and White subgroups, respectively. Treatment-emergent adverse events were similar across all subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Consistent with the overall study population, DAXI 40 U demonstrated a high response rate and duration of effect of \u226524 weeks across all age and race subgroups.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjac246","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T17:09:10Z","timestamp":1662829750000},"page":"205-214","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials"],"prefix":"10.1093","volume":"43","author":[{"given":"Nowell","family":"Solish","sequence":"first","affiliation":[{"name":"Division of Dermatology, University of Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl M","family":"Burgess","sequence":"additional","affiliation":[{"name":"Center for Dermatology and Dermatologic Surgery , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H","family":"Weinkle","sequence":"additional","affiliation":[{"name":"University of South Florida , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynis","family":"Ablon","sequence":"additional","affiliation":[{"name":"University of California Los Angeles (UCLA) , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Brown","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc. , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie","family":"Kooken","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc. , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman G","family":"Rubio","sequence":"additional","affiliation":[{"name":"Blue Obsidian Consulting LLC , Redwood City, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"issue":"3","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global aesthetics consensus: botulinum toxin type A\u2014evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1473-2165.2011.00593.x","article-title":"Advances in the use of botulinum neurotoxins in facial esthetics","volume":"11","author":"Flynn","year":"2012","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/ciia.2007.2.1.81","article-title":"Cosmetic use of botulinum toxin type A in the elderly","volume":"2","author":"Cheng","year":"2007","journal-title":"Clin Interv Aging"},{"issue":"3","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1524-4725.2009.01063.x","article-title":"A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI","volume":"35","author":"Grimes","year":"2009","journal-title":"Dermatol Surg"},{"issue":"5","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1097\/PRS.0000000000002119","article-title":"Global aesthetics consensus: hyaluronic acid fillers and botulinum toxin type A\u2014recommendations for combined treatment and optimizing outcomes in diverse patient populations","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"2023033111020738000_","first-page":"350","article-title":"Efficacy and safety of incobotulinumtoxin A for the correction of glabellar lines among patients with skin types IV to VI","volume":"14","author":"Jackson","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1524-4725.2012.02551.x","article-title":"AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data","volume":"38","author":"Taylor","year":"2012","journal-title":"Dermatol Surg"},{"issue":"Supplement_6","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.asj.2009.09.012","article-title":"An analysis of efficacy data from four Phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines","volume":"29","author":"Baumann","year":"2009","journal-title":"Aesthet Surg J"},{"issue":"1","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/prs.0000000000006327","article-title":"DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/dss.0000000000002531","article-title":"DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, Phase 3 safety study","volume":"47","author":"Fabi","year":"2021","journal-title":"Dermatol Surg"},{"issue":"1","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/dss.0000000000002463","article-title":"A large, open-label, Phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"},{"issue":"4","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/dss.0000000000002877","article-title":"Prior botulinum toxin treatment does not impact efficacy or safety in clinical trials: analysis of daxibotulinumtoxinA for injection in the SAKURA program","volume":"47","author":"Cohen","year":"2021","journal-title":"Dermatol Surg"},{"issue":"Supplement_3","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.1097\/dss.0000000000001330","article-title":"Efficacy and tolerability of incobotulinumtoxinA for treating glabellar frown lines in Korean adults: a postmarketing observational study","volume":"43","author":"Park","year":"2017","journal-title":"Dermatol Surg"},{"key":"2023033111020738000_","author":"Allergan"},{"issue":"1","key":"2023033111020738000_","first-page":"31","article-title":"Aging differences in ethnic skin","volume":"9","author":"Vashi","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12663-012-0407-1","article-title":"Botulinum toxin type A for the treatment of hyperkinetic lines of the face","volume":"12","author":"Chauhan","year":"2013","journal-title":"J Maxillofac Oral Surg"},{"issue":"12","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/dss.0000000000002237","article-title":"Racial and ethnic differences in self-assessed facial aging in women: results from a multinational study","volume":"45","author":"Alexis","year":"2019","journal-title":"Dermatol Surg"},{"issue":"12","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"e872","DOI":"10.1097\/gox.0000000000000507","article-title":"Aesthetic applications of botulinum toxin A in Asians: an international, multidisciplinary, pan-Asian consensus","volume":"4","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"4","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/dss.0000000000002864","article-title":"PrabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines in adult patients with skin of color: post hoc analyses of the US Phase III clinical study data","volume":"47","author":"Taylor","year":"2021","journal-title":"Dermatol Surg"},{"issue":"9","key":"2023033111020738000_","first-page":"1084","article-title":"Efficacy and safety of incobotulinumtoxinA in Asian subjects: a pooled analysis of clinical trials in the treatment of glabellar frown lines","volume":"15","author":"Seo","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/11530110-000000000-00000","article-title":"Botulinum toxin: examining duration of effect in facial aesthetic applications","volume":"11","author":"Flynn","year":"2010","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2023033111020738000_","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1097\/PRS.0b013e3181b5641b","article-title":"Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a Phase III, randomized, double-blind, placebo-controlled study","volume":"124","author":"Kane","year":"2009","journal-title":"Plast Reconstr Surg"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjac246\/47044136\/sjac246.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/43\/2\/205\/49714102\/sjac246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/43\/2\/205\/49714102\/sjac246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:02:34Z","timestamp":1680260554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/43\/2\/205\/6695383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,10]]},"published-print":{"date-parts":[[2023,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjac246","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,9,10]]}}}